Payment overview · 2025
General Payments
$37.73
2 reported records · 2 companies
Healthcare provider profile · identity verified
Dumitru Sandulescu, MD
Allopathic & Osteopathic Physicians|Family Medicine · STERLING HEIGHTS, MI · NPI 1104981695
Verified facts
What the public records show
CMS Open Payments records show Dumitru Sandulescu, MD received $37.73 in general payments during 2025 across 2 reported records.
Axsome Therapeutics, Inc. accounted for 53.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.10 | 53.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.63 | 46.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $37.73 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $20.10 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 105 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
105 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 779 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 422 | 75 |
| Gabapentin | Gabapentin | 400 | 57 |
| Omeprazole | Omeprazole | 399 | 79 |
| Lisinopril | Lisinopril | 383 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 63 |
| Trazodone Hcl | Trazodone Hcl | 378 | 53 |
| Simvastatin | Simvastatin | 362 | 64 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 293 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 290 | 55 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 271 | 42 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 234 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 233 | 49 |
| Ibuprofen | Ibuprofen | 229 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 226 | 47 |
| Furosemide | Furosemide | 199 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 196 | 23 |
| Metformin Hcl | Metformin Hcl | 187 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 34 |
| Baclofen | Baclofen | 169 | 31 |
| Promethazine Hcl | Promethazine Hcl | 161 | 57 |
| Trintellix | Vortioxetine Hydrobromide | 157 | 17 |
| Amoxicillin | Amoxicillin | 153 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 150 | 20 |
| Carvedilol | Carvedilol | 145 | 22 |
| Calcium Acetate | Calcium Acetate | 143 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 137 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 130 | 23 |
| Losartan Potassium | Losartan Potassium | 130 | 24 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 127 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 122 | 28 |
| Eliquis | Apixaban | 120 | 18 |
| Azithromycin | Azithromycin | 119 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 14 |
| Farxiga | Dapagliflozin Propanediol | 105 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 104 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 100 | 15 |
| Clonidine Hcl | Clonidine Hcl | 97 | 12 |
| Allopurinol | Allopurinol | 95 | 14 |
| Sertraline Hcl | Sertraline Hcl | 94 | 14 |
| Potassium Chloride | Potassium Chloride | 91 | 16 |
| Atenolol | Atenolol | 89 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 89 | 11 |
| Buspirone Hcl | Buspirone Hcl | 84 | 18 |
| Ammonium Lactate | Ammonium Lactate | 82 | 18 |
| Glimepiride | Glimepiride | 74 | 13 |
| Cephalexin | Cephalexin | 72 | 41 |
| Naproxen | Naproxen | 66 | 15 |
| Montelukast Sodium | Montelukast Sodium | 62 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 62 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | suppressed |
| Linzess | Linaclotide | 56 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 55 | suppressed |
| Nystatin | Nystatin | 55 | 15 |
| Trulicity | Dulaglutide | 55 | suppressed |
| Alprazolam | Alprazolam | 51 | suppressed |
| Bupropion Xl | Bupropion Hcl | 51 | suppressed |
| Lidocaine | Lidocaine | 51 | 11 |
| Bumetanide | Bumetanide | 50 | suppressed |
| Finasteride | Finasteride | 50 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Colchicine | Colchicine | 49 | suppressed |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Nitroglycerin | Nitroglycerin | 44 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 24 |
| Jardiance | Empagliflozin | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 39 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 39 | 11 |
| Glipizide | Glipizide | 37 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 33 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 13 |
| Cilostazol | Cilostazol | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Prednisone | Prednisone | 23 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 22 | suppressed |
| Ursodiol | Ursodiol | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Ribavirin | Ribavirin | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Enulose | Lactulose | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fingolimod | Fingolimod Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Bicalutamide | Bicalutamide | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $37.73 · 2 records | Axsome Therapeutics, Inc. | Auvelity, FARXIGA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error